Previous 10 | Next 10 |
2023-11-16 19:54:20 ET Summary NovoCure is an oncology company that offers a novel therapy for solid tumors called TTFields and comprehensive patient support services. Despite a challenging year, NovoCure's core business is healthy, with high margins and a large patient base. ...
Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 20...
2023-11-03 06:45:00 ET Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it. Medical device specialist Novocure (NASDAQ: NVCR) boasts one of the more innovative approac...
2023-10-26 16:35:22 ET Oncology-focused healthcare company Novocure (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its latest set of quarterly results. That decline was notably steep...
2023-10-26 11:17:02 ET NovoCure Limited (NVCR) Q3 2023 Earnings Conference Call October 26, 2023 08:00 ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief ...
2023-10-26 11:00:23 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2023 Earnings Call Oct 26, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2023 Earnings Call Transcript
2023-10-26 07:10:40 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth HC Wainwright cuts NovoC...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most a...
NovoCure Limited (NVCR) is expected to report $-0.51 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with supportive care alone Patients treated with TTFields therapy experienced prolonged quality of l...